Neoadjuvant PD-1 blockade in surgically resectable desmoplastic melanoma: cohort A of the phase 2 SWOG S1512 trial

By afschroeder • January 30, 2026

Kendra KL, Bellasea SL, Eroglu Z, Hu-Lieskovan S, Campbell KM, Carson WE 3rd, Wada DA, Plaza JA, In GK, Ikeguchi A, Hyngstrom J, Brohl AS, Chmielowski B, Khushalani NI, Markowitz J, Monroe M, Contreras CM, Bowles T, Norman K, Medina E, Gonzalez CR, Baselga-Carretero I, Garcilazo IP, Vega-Crespo A, Chen JM, Deen NNA, Patel SP, Grossmann KF, Sondak VK, Sharon E, Moon J, Wu MC, Ribas A. Neoadjuvant PD-1 blockade in surgically resectable desmoplastic melanoma: cohort A of the phase 2 SWOG S1512 trial. Nat Cancer. 2026 Jan 29. doi: 10.1038/s43018-025-01113-y. Epub ahead of print. PMID: 41611998.

Tags: Hematology/Oncology, Publications

daNIS-2: a phase III, randomized, double-blind study of the anti-TGF-β monoclonal antibody NIS793 or placebo in combination with nab-paclitaxel/gemcitabine as first-line treatment in patients with metastatic pancreatic ductal adenocarcinoma

Paulson S, Ikeda M, Shen L, Stein A, Macarulla T, Milella M, Golan T, Wainberg Z, Taieb J, Wang L, Polydoros F, Abecunas C, López[...]

Anti-trophoblast Cell-Surface Antigen 2 (TROP2)-Based Therapy for Concurrent Breast and Thyroid Malignancies

Berkowitz MJ, Arzoo KK. Anti-trophoblast Cell-Surface Antigen 2 (TROP2)-Based Therapy for Concurrent Breast and Thyroid Malignancies. Cureus. 2026 Oct 6;18(10):e117545. doi: 10.7759/cureus.117545. PMID: 42992212; PMCID:[...]

PADL1NK-005 study design: a phase III trial of fetrastobart vedotin (Fetra-V) vs docetaxel in patients with previously treated tumor PD-L1-positive NSCLC

Altan M, Navani V, Kim HR, Sun L, Paz-Ares L, Chmielewska I, Lin CC, Cuppens K, Mountzios I, Peled N, Cappuzzo F, Wang B, Zhou[...]